7:13AM Incyte beats by $0.01, beats on revs (INCY) 14.41 : Reports Q3 (Sep) loss of $0.42 per share, $0.01 better than the Capital IQ Consensus Estimate of ($0.43); revenues fell 0.6% year/year to $16.8 mln vs the $16.5 mln consensus. As of September 30, 2011, cash, cash equivalents and marketable securities totaled $317.0 mln compared to $424.2 mln as of December 31, 2010. Additionally, co adds that NDA for ruxolitinib as a treatment for myelofibrosis was filed and granted priority review by the FDA; PDUFA date set for December 3, 2011; Commercialization activities advance; sales force recruitment completed.
Market Data 
Markets 
AI
